Food Allergy Treatment Market Size, Share & Trends Analysis Report By Allergen Type (Dairy Products, Peanuts, Poultry Product), By Drug Type (Antihistamines, Decongestants), By Route of Administration, By End-use, By Region, And Segment Forecasts, 2024 - 2030

Food Allergy Treatment Market Size & Trends

The global food allergy treatment market size was estimated at USD 5.87 billion in 2023 and is projected to grow at a CAGR of 9.44% from 2024 to 2030. Key factors propelling the market growth include the rising prevalence of food allergies worldwide and increasing R&D activities for novel drugs. Moreover, the adoption of new biological agents to treat food allergies and an increase in clinic visits by patients seeking therapy for food allergies are likely to drive the market growth over the forecast period.

The increasing prevalence of food allergies such as dairy and peanuts, is especially common among children in Western nations. Peanut allergy, often persistent throughout life, typically manifests in early childhood and is associated with more severe reactions than other food allergies. Unlike many food allergies that resolve as children age, peanut allergies continue into adulthood for the majority. Traditionally, food allergy management focused on strict allergen avoidance and emergency action plans, including the availability of adrenaline auto-injectors. However, with the 2018 European Academy of Allergy and Clinical Immunology (EAACI) guidelines recommending Oral Immunotherapy (OIT) as a treatment option for children as young as 4 to 5 years old, there has been a shift toward more proactive management. This change acknowledges the growing prevalence of food allergies, driving the development of innovative treatments that enhance management and potentially reduce the severity of allergic reactions.

Food allergies such as peanut allergy affect about 1% to 2% of the U.S. population, so the need for effective treatments is more crucial than ever. Over the past 10 years, the prevalence of peanut allergy has increased. For instance, as per Food Allergy Treatment Research & Education, in 2022, approximately 32 million Americans have an illness, and 6.1 million of those have a peanut allergy. In addition, peanut allergy ranks among the most prevalent food allergies, impacting a staggering 17 million individuals across Europe.

The increase in funding for allergy treatments is driving advancements in research, development, and accessibility of innovative therapies, addressing the growing demand for more effective treatments & management strategies. This heightened financial support is propelling the market growth, fostering the development of safer and more accessible solutions for those affected by this condition. , in September 2022, COUR Pharmaceuticals, a clinical-stage biotechnology company, successfully completed a USD 30 million financing round, with Alpha Wave Ventures as the lead investor. This funding will support the expansion of COUR's innovative immune-modifying nanoparticles (COUR NanoParticles or CNPs) technology platform. Furthermore, it will facilitate the progression of the company's two human proof-of-concept studies focused on treating food allergies. This significant investment highlights the potential for advancing immune system reprogramming approaches to address autoimmune disorders and food allergies.

In June 2022, Alladapt Immunotherapeutics, Inc. successfully concluded a USD 119 million financing round, with Enavate Sciences, a Patient Square Capital portfolio company, taking the lead. Other participants include Gurnet Point Capital, along with new investors like Allerfund, Novartis, Red Tree Venture Capital, and WestRiver Group. These funds are expected to boost the ongoing clinical development of ADP101.

Market Concentration & Characteristics

The market is currently in a growth stage, with accelerated expansion driven by innovation and technological advancements. Product approvals and advancements in clinical trials propel this evolution. For instance, in December 2022, Aravax, a clinical-stage biotechnology company, initiated its series B funding round with a substantial USD 20 million investment from prominent Australian life science investors, Brandon Capital and Tenmile. This funding will empower Aravax to begin Phase 2 trials of PVX108 and seek additional capital to expedite its development efforts. Having received approval for its Investigational New Drug (IND) application from the U.S. FDA and a Clinical Trial Notification from Australia's Therapeutic Goods Administration (TGA), Aravax is set to progress its Phase 2 clinical trial program across the U.S. and Australia. Further funding will support the expansion of this study and hasten development toward Phase 3. This significant investment demonstrates strong investor confidence in advancing PVX108 into its Phase 2 development stage.

The market is also characterized by a moderately high level of merger and acquisition (M&A) and collaboration activity. The leading players, such as Nestlé; Aimmune Therapeutics, Inc. among others, are involved in M&A activities. For instance, in October 2020, Nestle SA completed the acquisition of Aimmune Therapeutics, Inc. This acquisition, conducted by Nestlé Health Science, represents a significant step in its ongoing commitment to delivering innovative, science-backed nutritional solutions that promote healthier lifestyles. The acquisition of Aimmune Therapeutics, notably for its ground-breaking product PALFORZIA, the first FDA-approved treatment for peanut allergies, is seen as a transformative move.

In the global market, regulatory trends are evolving to ensure greater safety and accessibility for patients. Regulatory agencies like the U.S. FDA are increasingly receptive to reviewing and approving no injectable treatments, reflecting a shift toward more patient-friendly options. These agencies are also emphasizing rigorous allergen labeling and traceability measures to protect consumers. The introduction of stricter guidelines for allergen labeling and the evaluation of innovative treatment options is fostering a more favorable regulatory environment, promoting improved patient care and quality of life for food allergy sufferers.

The threat of substitutes is generally low, as there are limited direct substitutes for specialized food allergy treatments. While allergen avoidance and emergency response measures can help manage food allergies, these are not substitutes for medical treatments. However, off-label use of products or medications not specifically developed for food allergies can be a potential substitute in some cases, though their efficacy and safety may vary, making them less reliable substitutes.

The market is expanding regionally, enhancing accessibility of therapeutics across diverse healthcare facilities nationwide. This strategy ensures wider availability across geographic areas, extending market presence and enabling patients in different regions to access a variety of treatments.

Allergen Type Insights

Based on allergen type, the peanuts segment led the market with the largest revenue share of 26.62% in 2023. Key factors propelling market growth include, rising prevalence of peanut allergies worldwide and increasing R&D activities for novel drugs. Moreover, growing adoption of new biological agents to treat allergies and an increase in clinic visits by patients seeking therapy for this allergy are likely to drive market growth over forecast period.

The wheat segment is projected to grow at the fastest CAGR over the forecast period. In the wheat segment, there's a surge in awareness prompting a growing demand for wheat-free alternatives. Factors driving this market include the rise in diagnosed cases of wheat allergies, gluten sensitivities, and celiac disease, alongside the health and wellness trend. In addition, the availability of a wider range of alternative grains and ingredients, coupled with continuous product innovation, is attracting more consumers to this segment. As a result, the wheat-free market is experiencing steady growth, with expectations for further expansion in the foreseeable future.

Drug Type Insights

Based on drug type, the epinephrine segment led the market with the largest revenue share of 18.17% in 2023. Epinephrine is considered to be the medication of choice for treatment of allergic conditions. Organizations such as the FDA and CDC recommend the use of epinephrine as the initial treatment of choice for emergency allergic conditions. The introduction of cost-effective epinephrine auto-injectors by key companies is expected to significantly augment market growth. For instance, Impax Laboratories, Inc. developed a prefilled auto injector named “Impax Epinephrine Auto-Injector” indicated for the management of life-threatening, allergic emergencies. Such introductions are anticipated increase adoption of auto-injectable epinephrine products and drive the market. Furthermore, these injectors are disposable and facilitate self-administration, which fulfils the consumer requirement of ease-of-use and higher efficacy. EpiPen, and Adrenaclick are some of the examples for this drug category.

The immunotherapy segment is projected to grow at a fastest CAGR over the forecast period, driven by drugs such as Xolair and PALFORZIA. In January 2020, the FDA's approval of PALFORZIA marked a significant milestone in Food Allergy Treatment. PALFORZIA addresses a crucial unmet medical need by providing a treatment option for peanut allergies. Prior to its approval, patients had limited choices beyond strict avoidance, and this approval introduced a potentially life-changing solution. This oral immunotherapy product is specifically indicated for mitigating allergic reactions, including anaphylaxis that might occur from accidental peanut exposure in children aged 4 to 17 years with a confirmed diagnosis of peanut allergy. The FDA's requirement for a Risk Evaluation and Mitigation Strategy (REMS) ensures the safe and controlled administration of PALFORZIA, boosting patient safety and healthcare provider confidence. PALFORZIA, used alongside a peanut-avoidant diet, is tailored to meet the needs of patients while being contraindicated in cases of uncontrolled asthma and eosinophilic esophagitis and other eosinophilic gastrointestinal diseases, further emphasizing its safety and suitability for specific patient populations.

Route Of Administration Insights

Based on route of administration, the parenteral segment led the market with the largest revenue share of 60.06% in 2023, because they are poised to maintain dominance in the space. Epinephrine is the primary medication for anaphylaxis treatment, preferably administered via Intramuscular (IM) injection into the lateral thigh. Although Intravenous (IV) administration is an option, it is primarily restricted to inpatient settings as it requires proper monitoring. Although antihistamines, corticosteroids, and bronchodilators can be used as supportive therapies, they do not target the underlying condition directly. IV fluids are crucial to prevent and manage tissue hypo perfusion.

The oral segment is projected to grow at the fastest CAGR of 10.14% over the forecast period. Oral food allergy treatment primarily employs Oral Immunotherapy (OIT), involving the gradual consumption of controlled amounts of food allergen. OIT offers several distinct advantages for individuals with peanut allergies. It aims to desensitize patients, reducing the severity of allergic reactions when exposed to food allergy. This can be a life-changing improvement for those who live in constant fear of accidental peanut exposure. OIT also serves as a safety net, mitigating the risks associated with unintended contact with allergens, which can be especially vital in emergencies. Furthermore, successful OIT can improve the overall quality of life, allowing individuals to dine with less anxiety and potentially reintroduce allergens into their diet, broadening their food choices.

End-use Insights

Based on end-use, the hospital pharmacies segment led the market with the largest revenue share of 40.18% in 2023. Hospital pharmacies serve as a critical distribution channel, facilitating the availability and efficient dispensation of medications and treatments essential for managing food allergies within a hospital environment. Several prominent market drivers deeply influence this role.

The increasing prevalence of food allergies has led to a growing demand for treatments, making it crucial for hospital pharmacies to meet this demand effectively. In addition, stringent allergen labeling regulations have underscored the need for prompt access to allergies in hospital settings.

The retail pharmacies segment is projected to grow at the fastest CAGR over the forecast period, because the retail pharmacies play a pivotal role as a distribution channel. They provide patients with crucial access to allergy medications and products, ensuring that individuals have the means to manage their condition effectively. The significance of retail pharmacies lies in their accessibility, as they are often conveniently located for patients, allowing them to promptly obtain prescription medications and over-the-counter products, thereby enhancing the overall quality of care and improving the well-being of those dealing with food allergies. Retail pharmacies are crucial in making these essential treatments widely available to those in need.

Regional Insights

North America dominated the food allergy treatment market with the revenue share of 36.44% in 2023. The region held a major market share due to an increase in understanding of the high potential associated with allergy drugs. This has driven U.S.-based firms to make considerable investments in the development of these drugs. Moreover, new players are entering the market with their novel products, which is expected to intensify competitive rivalry in North American market.

U.S. Food Allergy Treatment Market Trends

The food allergy treatment market in U.S. is anticipated to grow at the fastest CAGR over the forecast period. In the U.S. market, Nestlé's Palforzia faced significant challenges. Despite a substantial investment of USD 2.6 billion in its development, the treatment regimen proved to be too cumbersome for many potential patients. When Palforzia entered the market in 2020, physicians were initially excited to offer it to their patients. However, the COVID-19 pandemic disrupted in-person treatment plans. As a result, doctors resorted to informing approximately 1,000 patients about the new drug as an option for post-pandemic use.

Surprisingly, only six individuals expressed interest in the treatment that had been heralded as an efficient solution for life-threatening peanut allergy, having received clearance from U.S. authorities. Even after 3 years, many physicians have not prescribed Palforzia. Across the U.S., it appears that doctors & patients are opting for the traditional approach of avoiding allergens and carrying adrenaline injections for emergencies instead. As a significant development in the market, Nestlé divested its Palforzia business in September 2023 to Stallergenes Greer, a biopharmaceutical company specializing in allergy diagnosis and treatment. This strategic move followed Nestlé's earlier announcement of a review of Palforzia, with Nestlé set to receive milestone payments and ongoing royalties from Stallergenes Greer as part of the agreement.

Europe Food Allergy Treatment Market Trends

The food allergy treatment market in Europe is projected to exhibit at a significant CAGR over the forecast period, due to the presence of developed economies, such as Germany, Spain, the UK, France, and Italy. These countries have advanced infrastructure, which is anticipated to significantly boost clinical research prospects in the region. Moreover, the market growth can be attributed to a growing biotechnology industry and rising investments in R&D, which is expected to boost the market growth.

The UK food allergy treatment market is expected to grow at the fastest CAGR over the forecast period. According to Food Standards Agency data, on average, about 2 million people are living with diagnosed Food Allergy Treatment and about 600,000 with celiac disease. About 3% of the UK population has IgE-mediated food allergies and is at risk of possibly life-threatening reactions to allergies.

The food allergy treatment market in France is expected to grow at a substantial CAGR over the forecast period. As per the study “Allergy Prevalence in France and Skin Impact - Epidemiological Survey of a Representative Sample of French Adults” released in July 2021, it is projected that on average, about 10 million French adults have one or the other kind of allergy. The study included 2,036 adults, out of which 20.2% of French adults reported allergies.

The Germany food allergy treatment market is expected to grow at a significant CAGR over the forecast period. In Germany, allergies are quite common, with roughly one-fifth of the population experiencing some form of allergy. However, it is worth noting that only about one-tenth of these individuals receive appropriate treatment.

Asia Pacific Food Allergy Treatment Market Trends

The food allergy treatment market in Asia Pacific exhibits some key variations. Some countries, such as Australia, face a relatively high prevalence of peanut allergies and others, such as China, show lower incidence rates. Understanding these regional disparities is crucial for market stakeholders. It is essential to recognize the diverse trends and adapt strategies accordingly. Moreover, Traditional Chinese Medicine (TCM) is gaining attention due to its potential to address allergies. The long-standing reputation of TCM for effectiveness, cost-efficiency, & safety is attracting interest in China and Western societies. However, there is a need to carefully consider how TCM may impact the broader modern medicine market.

The China food allergy treatment market is expected to grow at a moderate CAGR over the forecast period. Food allergies appear to be a significant concern in Western countries but are notably less prevalent in other parts of the world, particularly in China. For instance, in Beijing, food allergies represent only a small percentage, ranging from 3.4% to 5.0% of all allergies, and these allergies are primarily associated with foods such as fish, shrimp, seaweed, and crab, rather than peanuts.

The food allergy treatment market in Japan is expected to grow at the fastest CAGR over the forecast period, due to rapidly expanding market, with Japanese pharma firms entering the space and observing growing demand due to lifestyle changes. In June 2021, Astellas Pharma, Inc. made a significant decision regarding the development of ASP0892, a DNA vaccine for food allergy, which was in phase 1 study. The company announced the termination of its development, marking a pivotal shift in its approach to addressing peanut allergies.

Latin America Food Allergy Treatment Market Trends

Thefood allergy treatment market in Latin America is expected to grow at a moderate CAGR during the forecast period. This market is diverse, with varying prevalence of peanut allergy across different countries in the region. In some countries like Brazil and Mexico, food allergies are more common, while in others, the prevalence is lower. This variance in disease prevalence directly influences the size and dynamics of the treatment industry in each country.

The Brazil food allergy treatment market is expected to grow at the fastest CAGR over the forecast period. In Brazil, allergies to tree nuts, particularly Brazil nuts, are not uncommon, and they can be quite severe. These allergies typically manifest by the age of 2 years, and some individuals may become allergic to more types of tree nuts as they grow older.

Middle East & Africa Food Allergy Treatment Market Trends

The food allergy treatment market in Middle East and Africa is marked by varying prevalence rates across different countries. Although the prevalence of peanut allergy is relatively low in some areas, there is a growing concern in several countries. The market scenario is diverse, with some countries relying on traditional treatments and others exploring innovative approaches. Key players in this market need to adapt to this regional diversity and cater to the specific needs of each country.

The Saudi Arabia food allergy treatment market is anticipated to grow at the fastest CAGR over the forecast period. The competitive landscape in the Saudi Arabia market may differ from regions with higher prevalence rates. Although the market may not be as extensive, there is still a demand for treatments and solutions that cater to the needs of those affected. Key players in the market should focus on providing accessible & affordable treatments, along with education and support for patients and their families.

Key Food Allergy Treatment Company Insights

Some of the leading players in the industry include, Teva Pharmaceuticals Industries Ltd., Nestle SA (Aimmune Therapeutics Inc.), Teva Pharmaceuticals Industries Ltd., Sanofi, among other. Different strategies are taken by the players to strengthen their market positions. Companies are involved in expanding their market presence by signing agreements with other players in emerging economies. Product approval is another strategy adopted by these companies.

Emerging players such as Aravax, Vedanta Biosciences, Inc. and Vedanta Biosciences, Inc. are taking different strategic initiatives such as collaborations & partnerships with key participants and other players in the industry to enhance their presence. Capturing niche areas of supply chain, such as distribution and delivery of products & solutions, to establish themselves.

Recent Developments

• In September 2023, Stallergenes Greer, a prominent global healthcare company specializing in Allergen Immunotherapy (AIT), announced global agreements with Nestlé to utilize the peanut allergy oral immunotherapy treatment Palforzia. This move enhances Stallergenes Greer's position in the AIT field, expanding its portfolio to provide tailored AIT treatments for patients & healthcare providers. These treatments encompass a wide array of administration methods to cater to individual needs

• In May 2023, DBV Technologies has made an announcement that the results of its Phase 3 EPITOPE trial involving EPIT using Viaskin Peanut in children aged 1 to 3 years have been published in the New England Journal of Medicine. This publication underscores the potential of a new treatment option for this specific age group, offering hope for the management of food allergies in young children

• In June 2023, Alladapt Immunotherapeutics, Inc. unveiled topline results of Phase 1/2 Harmony study assessing effectiveness & safety of ADP101 for treating food allergies. Outcomes indicate dose-dependent, clinically significant responses, and a favorable safety profile in pediatric patients with single or multiple food allergies. These promising findings suggest ADP101's potential as a safe and effective treatment for children with common food allergies

Food Allergy Treatment Market Report Scope

Report Attribute	Details
Market size value in 2024	USD 6.47 billion
Revenue forecast in 2030	USD 11.12 billion
Growth rate	CAGR of 9.44% from 2024 to 2030
Base year for estimation	2023
Historical data	2018 - 2022
Forecast period	2024 - 2030
Quantitative units	Revenue in USD million/billion and CAGR from 2024 to 2030
Report coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered	Drug type, allergen type, route of administration, end-use, region
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; UK; Germany; Spain; Denmark, Sweden, Norway, France; Italy; China; India; Japan, Thailand, South Korea; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE, Kuwait
Key companies profiled	Sanofi; Aimmune Therapeutics (Nestle SA); DBV Technologies; Vedanta Biosciences, Inc.; Alladapt Immunotherapeutics, Inc.; COUR Pharmaceuticals; Aravax; Prota Therapeutics; Teva Pharmaceuticals
Customization scope	Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

 

Global Food Allergy Treatment Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the food allergy treatment market report based on allergen type, drug type, route of administration, end-use and region.

• Allergen Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Dairy Products

  • Poultry Product

  • Tree Nuts

  • Peanuts

  • Shellfish

  • Wheat

  • Soys

  • Other

• Drug Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Antihistamines

  • Decongestants

  • Corticosteroids

  • Mast Cell Stabilizers

  • Leukotriene Inhibitors

  • Nasal Anti-cholinergic

  • Immuno-modulators

  • Epinephrine

  • Immunotherapy

    • Xolair

    • PALFORZIA

    • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Others

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Parenteral

  • Oral

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait